Report : Asia Pacific Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Analysis, and Others), Therapeutic Application (Oncology, Infectious Diseases, Neurological Disorders, Autoimmune Diseases, Gynecological Disorders, Cardiovascular Diseases, Respiratory Disorders, and Others), and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization, and Others)
at 8.1% CAGR, Asia Pacific Pharmacokinetics Services Market is Projected to be Worth US$ 356.58 Million by 2031, says Business Market Insights
According to Business Market Insights' research, the Asia Pacific pharmacokinetics services market was valued at US$ 191.44 million in 2023 and is expected to reach US$ 356.58 million by 2031, registering a CAGR of 8.1% from 2023 to 2031. Increasing adoption of big data analytics in pharmacokinetics services and increasing adoption of in-vivo and in-vitro models for understanding variability in pharmacokinetics are among the critical factors attributed to drive the Asia Pacific pharmacokinetics services market growth.
Pharmaceutical companies adopting pharmacokinetics services opt for Big Data analytics to leverage large data sets, which subsequently aids in enhanced understanding of the drug discovery process. Big data and analytics can also help in the development of Customizable Decision Support System (CDS). This system helps integrate drug-specific information on efficacy, safety, pharmacokinetics, and pharmacodynamics. It also assists healthcare professionals in personalized medicine by tailoring specific treatments based on characteristics of individual patients. CDS analytical method allows the identification of trends, correlation, and patterns that may not be determined using traditional methods of drug discovery. It also helps facilitate predictive model development that can forecast drug behavior. Thus, the increasing adoption of big data analytics is emerging as a new trend in the Asia Pacific pharmacokinetics services market.
On the contrary, limited reach of pharmacokinetics service providers in emerging countries hampers the growth of Asia Pacific pharmacokinetics services market.
Based on drug type, the Asia Pacific pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held 50.2% market share in 2023, amassing US$ 96.15 million. It is projected to garner US$ 186.59 million by 2031 to register 8.6% CAGR during 2023-2031.
In terms of service type, the Asia Pacific pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held 35.5% share of Asia Pacific pharmacokinetics services market in 2023, amassing US$ 67.92 million. It is anticipated to garner US$ 137.08 million by 2031 to expand at 9.2% CAGR during 2023-2031.
By therapeutic application, the Asia Pacific pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held 22.4% market share in 2023, amassing US$ 42.84 million. It is projected to garner US$ 88.07 million by 2031 to register 9.4% CAGR during 2023-2031.
By end user, the Asia Pacific pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held 43.4% market share in 2023, amassing US$ 83.00 million. It is projected to garner US$ 163.03 million by 2031 to register 8.8% CAGR during 2023-2031.
By country, the Asia Pacific pharmacokinetics services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that Japan captured 25.5% share of Asia Pacific pharmacokinetics services market in 2023. It was assessed at US$ 48.76 million in 2023 and is likely to hit US$ 106.90 million by 2031, registering a CAGR of 10.3% during 2023-2031.
Key players operating in the Asia Pacific pharmacokinetics services market are Allucent; Certara Inc.; Charles River Laboratories International Inc; Eurofins Scientific SE; PACIFIC BIOLABS; Parexel International Corp; SGS SA; Shanghai Medicilon Inc.; and Thermo Fisher Scientific Inc, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com